A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers [clinicaltrials:NCT00000871]
A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers [clinicaltrials:NCT00000871]
Bio2RDF identifier
NCT00000871
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00000871
identifiers.org URI
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
To expand the available ...... nned as "follow-up" therapy.]
brief title [clinicaltrials_vocabulary:brief-title]
A Phase II Safety and Immunoge ...... -1 Uninfected Adult Volunteers
completion date [clinicaltrials_vocabulary:completion-date]
2000-01-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
In previous ALVAC vCP20 ...... of version 3.0 is cancelled.]
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
enrollment [clinicaltrials_vocabulary:enrollment]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
1999-11-02T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
keyword [clinicaltrials_vocabulary:keyword]
AIDS Vaccines
Avipoxvirus
HIV Preventive Vaccine
HIV Seronegativity
Vaccines, Synthetic
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2012-05-16T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00000871
official title [clinicaltrials_vocabulary:official-title]
A Phase II Safety and Immunoge ...... -1 Uninfected Adult Volunteers
org study id [clinicaltrials_vocabulary:org-study-id]
AVEG 202/HIVNET 014
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
reference [clinicaltrials_vocabulary:reference]
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
HIVNET 014
source [clinicaltrials_vocabulary:source]
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2012-05-01T00:00:00Z
identifier
clinicaltrials:NCT00000871
title
A Phase II Safety and Immunoge ...... -1 Uninfected Adult Volunteers
@en
type
label
A Phase II Safety and Immunoge ...... s [clinicaltrials:NCT00000871]
@en